Alto Neuroscience, Inc. $ANRO Shares Sold by SCS Capital Management LLC

SCS Capital Management LLC decreased its stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 50.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 33,389 shares of the company’s stock after selling 33,388 shares during the quarter. SCS Capital Management LLC’s holdings in Alto Neuroscience were worth $594,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Torren Management LLC acquired a new position in Alto Neuroscience during the fourth quarter worth approximately $62,000. Vanguard Personalized Indexing Management LLC increased its position in Alto Neuroscience by 13.7% during the third quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after purchasing an additional 2,055 shares during the last quarter. AlphaCore Capital LLC increased its position in Alto Neuroscience by 100.0% during the fourth quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $356,000 after purchasing an additional 10,000 shares during the last quarter. AQR Capital Management LLC acquired a new position in Alto Neuroscience during the first quarter worth approximately $52,000. Finally, Invesco Ltd. acquired a new position in Alto Neuroscience during the first quarter worth approximately $67,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on ANRO shares. JonesTrading dropped their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Bank of America initiated coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective for the company. Weiss Ratings raised shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Finally, Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Price Performance

Alto Neuroscience stock opened at $18.76 on Wednesday. Alto Neuroscience, Inc. has a 52-week low of $2.15 and a 52-week high of $28.44. The firm has a fifty day moving average of $22.94 and a 200-day moving average of $19.16. The firm has a market capitalization of $658.15 million, a P/E ratio of -7.75 and a beta of 1.22. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.